
A mostly overlooked component of CAR-T cells has a surprisingly strong effect on the cancer-fighting cells’ behavior, scientists reported on Tuesday, including in ways that might affect their safety and efficacy.
The component is called the co-stimulatory domain, and the two CAR-T therapies approved last year to treat forms of leukemia and lymphoma — Yescarta and Kymriah — use different ones.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Great article
Thanks
Juan
Interesting